These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 11574931)
1. A comparison of normal and leukemic stem cell biology in Chronic Myeloid Leukemia. Jørgensen HG; Holyoake TL Hematol Oncol; 2001 Sep; 19(3):89-106. PubMed ID: 11574931 [TBL] [Abstract][Full Text] [Related]
2. Chronic myelogenous leukemia: molecular and cellular aspects. Pasternak G; Hochhaus A; Schultheis B; Hehlmann R J Cancer Res Clin Oncol; 1998; 124(12):643-60. PubMed ID: 9879825 [TBL] [Abstract][Full Text] [Related]
3. Molecular pathogenesis of chronic myeloid leukemia: implications for new therapeutic strategies. Warmuth M; Danhauser-Riedl S; Hallek M Ann Hematol; 1999 Feb; 78(2):49-64. PubMed ID: 10089019 [TBL] [Abstract][Full Text] [Related]
4. Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy. Ali MA Mol Diagn Ther; 2016 Aug; 20(4):315-33. PubMed ID: 27220498 [TBL] [Abstract][Full Text] [Related]
5. Molecular biology of chronic myeloid leukemia. Maru Y Int J Hematol; 2001 Apr; 73(3):308-22. PubMed ID: 11345196 [TBL] [Abstract][Full Text] [Related]
7. Activation of hematopoietic growth factor signal transduction pathways by the human oncogene BCR/ABL. Sattler M; Salgia R Cytokine Growth Factor Rev; 1997 Mar; 8(1):63-79. PubMed ID: 9174663 [TBL] [Abstract][Full Text] [Related]
8. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. Li S; Ilaria RL; Million RP; Daley GQ; Van Etten RA J Exp Med; 1999 May; 189(9):1399-412. PubMed ID: 10224280 [TBL] [Abstract][Full Text] [Related]
9. Induction of Chronic Myeloid Leukemia in Mice. Zhang H; Li S Methods Mol Biol; 2016; 1465():17-25. PubMed ID: 27581135 [TBL] [Abstract][Full Text] [Related]
10. Chronic myelogenous leukemia as a paradigm of early cancer and possible curative strategies. Clarkson B; Strife A; Wisniewski D; Lambek CL; Liu C Leukemia; 2003 Jul; 17(7):1211-62. PubMed ID: 12835715 [TBL] [Abstract][Full Text] [Related]
11. Clinical and biological aspects of Philadelphia-negative/BCR-negative chronic myeloid leukemia. Costello R; Sainty D; Lafage-Pochitaloff M; Gabert J Leuk Lymphoma; 1997 Apr; 25(3-4):225-32. PubMed ID: 9168433 [TBL] [Abstract][Full Text] [Related]
13. Targeting Abnormal Hematopoietic Stem Cells in Chronic Myeloid Leukemia and Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms. Yung Y; Lee E; Chu HT; Yip PK; Gill H Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33440869 [TBL] [Abstract][Full Text] [Related]
14. Targeting of the BLT2 in chronic myeloid leukemia inhibits leukemia stem/progenitor cell function. Xiao M; Ai H; Li T; Rajoria P; Shahu P; Li X Biochem Biophys Res Commun; 2016 Apr; 472(4):610-6. PubMed ID: 26966074 [TBL] [Abstract][Full Text] [Related]
15. Leukemia cell lines: in vitro models for the study of Philadelphia chromosome-positive leukemia. Drexler HG; MacLeod RA; Uphoff CC Leuk Res; 1999 Mar; 23(3):207-15. PubMed ID: 10071072 [TBL] [Abstract][Full Text] [Related]
16. Hematopoietic stem cells in chronic myeloid leukemia. Petzer AL; Gunsilius E Arch Med Res; 2003; 34(6):496-506. PubMed ID: 14734089 [TBL] [Abstract][Full Text] [Related]